THERADIAG announced the launch of two additional kits in its i-Tracker® tests range. Theradiag is extending its range with two additional i-Tracker® test kits: i-Tracker® Certolizumab and i-Tracker® Anti-Certolizumab, all adapted to the i-Track10®, its random-access automated system, and to the IDS-iSYS automated analyzer manufactured by the IDS company. The CE marking of these two new i-Tracker® kits has been completed and their marketing has been declared to the French National Agency for the Safety of Medicines and Health Products (ANSM).

The Certolizumab kits are dedicated to the monitoring of biotherapies used in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, spondylarthritis and psoriasis, but also Crohn's disease in the United States, in Canada and in Switzerland at this stage. The i-Tracker® range now consists of 14 kits that can be used to treat a wide range of diseases.